HexarelinvsMK-677

Hexarelin is a synthetic hexapeptide (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2) that acts as one of the most potent agonists of the growth hormone secretagogue receptor (GHS-R1a). Its strong receptor affinity produces the highest GH release amplitude among the GHRP family, but this potency comes with broader neuroendocrine activation compared to more selective agents like ipamorelin.

At the pituitary level, hexarelin binding to GHS-R1a activates Gq/11-coupled phospholipase C, generating IP3 and DAG. IP3-mediated calcium release from intracellular stores triggers massive GH vesicle exocytosis. The strong GH response also comes with significant stimulation of cortisol (via ACTH release from corticotrophs) and prolactin release from lactotrophs — side effects that limit its clinical utility compared to more selective secretagogues.

Uniquely among GHRPs, hexarelin demonstrates significant cardioprotective properties independent of GH release. GHS-R1a receptors are expressed on cardiomyocytes, and hexarelin binding activates survival signaling through the PI3K/Akt and ERK1/2 pathways, protecting cardiac cells from ischemia-reperfusion injury and apoptosis. Hexarelin also binds to the scavenger receptor CD36 on macrophages and cardiac tissue, which may contribute to its anti-atherosclerotic and cardioprotective effects. Animal studies have demonstrated reduced infarct size and improved cardiac function following hexarelin administration. However, a significant practical limitation is desensitization — continuous hexarelin use leads to progressive reduction in GH response within 2-4 weeks, necessitating cycling protocols to maintain effectiveness.

MK-677 (Ibutamoren) is a non-peptide spiropiperidine compound that functions as a potent, orally active agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a). Unlike peptide-based GH secretagogues that require injection, MK-677 is resistant to gastrointestinal degradation and has excellent oral bioavailability, making it unique among compounds that stimulate GH release through the ghrelin receptor.

Upon binding GHS-R1a in the anterior pituitary, MK-677 activates the Gq/11-coupled PLC/IP3/calcium signaling pathway, triggering GH vesicle exocytosis. It also acts on GHS-R1a receptors in the hypothalamus, stimulating GHRH neurons in the arcuate nucleus while suppressing somatostatin tone, further amplifying the GH secretory signal. Importantly, MK-677 preserves the endogenous pulsatile pattern of GH release — it amplifies pulse amplitude rather than creating a flat, sustained elevation.

The 24-hour half-life means a single daily dose maintains elevated GH and IGF-1 levels around the clock. In clinical studies, MK-677 increased IGF-1 levels by 40-60% in elderly subjects, with sustained effects over 12 months without significant tachyphylaxis. However, its ghrelin-mimetic activity also activates hypothalamic appetite circuits (orexigenic neurons expressing NPY/AgRP), producing the notable increase in hunger that many users report. The compound also has mild cortisol-raising effects and can impair insulin sensitivity with prolonged use, likely through sustained GH-mediated antagonism of insulin signaling in peripheral tissues. Despite promising clinical data for muscle wasting and osteoporosis, MK-677 has not completed the FDA approval process.